All In Biotech

Drug Trial Radar · NCT00199381

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.

Last checked: Nov 20, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

504

Actual

Start

Oct 2005

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
Collaborators
Kyowa Kirin Co., Ltd.
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.

Conditions

  • Parkinson's Disease

Interventions

  • IstradefyllineDrug

    Oral istradefylline (KW-6002) 20 or 40 mg once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as Measured by Adverse EventsTime frame: Every 2 months up to 32 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyowa Pharmaceutical Inc.

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.